TNFAIP8 | OmnibusX

I. Expression across cell types

Name	Number of supported studies	Average coverage
B cell	41 studies	37% ± 10%	Explore
CD4-positive, alpha-beta T cell	34 studies	36% ± 10%	Explore
natural killer cell	33 studies	24% ± 7%	Explore
CD8-positive, alpha-beta T cell	30 studies	29% ± 8%	Explore
T cell	28 studies	32% ± 10%	Explore
macrophage	26 studies	28% ± 11%	Explore
regulatory T cell	25 studies	34% ± 9%	Explore
memory B cell	20 studies	37% ± 7%	Explore
naive B cell	20 studies	36% ± 8%	Explore
conventional dendritic cell	20 studies	27% ± 12%	Explore
mast cell	19 studies	33% ± 14%	Explore
naive thymus-derived CD4-positive, alpha-beta T cell	18 studies	39% ± 10%	Explore
monocyte	17 studies	26% ± 9%	Explore
mature NK T cell	17 studies	28% ± 10%	Explore
dendritic cell	16 studies	38% ± 15%	Explore
gamma-delta T cell	15 studies	27% ± 10%	Explore
mucosal invariant T cell	14 studies	37% ± 8%	Explore
classical monocyte	13 studies	29% ± 13%	Explore
naive thymus-derived CD8-positive, alpha-beta T cell	13 studies	34% ± 8%	Explore
CD16-negative, CD56-bright natural killer cell, human	12 studies	27% ± 7%	Explore
CD8-positive, alpha-beta memory T cell	11 studies	29% ± 10%	Explore
CD16-positive, CD56-dim natural killer cell, human	11 studies	24% ± 6%	Explore
CD4-positive, alpha-beta memory T cell	10 studies	35% ± 10%	Explore
effector memory CD8-positive, alpha-beta T cell	10 studies	34% ± 8%	Explore
myeloid cell	10 studies	29% ± 12%	Explore
non-classical monocyte	9 studies	32% ± 8%	Explore
basal cell	9 studies	24% ± 11%	Explore
adipocyte	9 studies	48% ± 15%	Explore
leukocyte	8 studies	33% ± 12%	Explore
effector CD8-positive, alpha-beta T cell	7 studies	24% ± 5%	Explore
mononuclear phagocyte	7 studies	30% ± 10%	Explore
T follicular helper cell	7 studies	42% ± 6%	Explore
innate lymphoid cell	6 studies	26% ± 3%	Explore
plasma cell	6 studies	30% ± 11%	Explore
effector memory CD4-positive, alpha-beta T cell	6 studies	38% ± 13%	Explore
plasmacytoid dendritic cell	6 studies	23% ± 6%	Explore
CD4-positive helper T cell	5 studies	27% ± 8%	Explore
effector CD4-positive, alpha-beta T cell	5 studies	34% ± 12%	Explore
smooth muscle cell	5 studies	17% ± 2%	Explore
mesothelial cell	5 studies	25% ± 13%	Explore
connective tissue cell	5 studies	20% ± 4%	Explore
exhausted T cell	4 studies	29% ± 9%	Explore
hematopoietic precursor cell	4 studies	39% ± 24%	Explore
epithelial cell	4 studies	29% ± 14%	Explore
immature B cell	4 studies	35% ± 6%	Explore
lymphocyte	4 studies	48% ± 13%	Explore
fibroblast	4 studies	25% ± 7%	Explore
granulocyte	4 studies	40% ± 27%	Explore
ciliated cell	4 studies	26% ± 6%	Explore
T-helper 17 cell	4 studies	32% ± 9%	Explore
effector memory CD8-positive, alpha-beta T cell, terminally differentiated	4 studies	34% ± 8%	Explore
double negative thymocyte	4 studies	37% ± 10%	Explore
platelet	3 studies	20% ± 1%	Explore
extravillous trophoblast	3 studies	30% ± 14%	Explore
precursor B cell	3 studies	29% ± 10%	Explore
germinal center B cell	3 studies	34% ± 5%	Explore
intermediate monocyte	3 studies	27% ± 16%	Explore
neutrophil	3 studies	39% ± 12%	Explore
pericyte	3 studies	30% ± 17%	Explore
myofibroblast cell	3 studies	21% ± 4%	Explore
alveolar macrophage	3 studies	27% ± 9%	Explore
group 3 innate lymphoid cell	3 studies	34% ± 15%	Explore
keratinocyte	3 studies	18% ± 1%	Explore
T-helper 1 cell	3 studies	41% ± 2%	Explore
central memory CD4-positive, alpha-beta T cell	3 studies	48% ± 4%	Explore
central memory CD8-positive, alpha-beta T cell	3 studies	33% ± 11%	Explore
CD4-positive, alpha-beta cytotoxic T cell	3 studies	23% ± 6%	Explore
abnormal cell	3 studies	28% ± 11%	Explore
microglial cell	3 studies	25% ± 6%	Explore

II. Expression across tissues

Name	Number of supported studies	Average coverage
peripheral blood	16 studies	29% ± 7%	Explore
lung	8 studies	25% ± 8%	Explore
liver	5 studies	23% ± 5%	Explore
bone marrow	4 studies	25% ± 8%	Explore
placenta	3 studies	27% ± 10%	Explore
intestine	3 studies	21% ± 1%	Explore
adipose	3 studies	22% ± 2%	Explore
lymph node	3 studies	35% ± 4%	Explore

Tissue	GTEx Coverage	GTEx Average TPM	GTEx Number of samples	TCGA Coverage	TCGA Average TPM	TCGA Number of samples
uterus	100%	1030.78	170 / 170	97%	15.63	446 / 459
thymus	100%	1359.79	652 / 653	97%	14.81	586 / 605
lung	100%	1831.37	577 / 578	97%	12.09	1116 / 1155
esophagus	100%	1325.49	1439 / 1445	97%	10.90	177 / 183
prostate	100%	1393.87	244 / 245	95%	12.51	478 / 502
pancreas	98%	928.05	323 / 328	94%	12.38	168 / 178
breast	100%	1664.29	459 / 459	91%	8.75	1020 / 1118
bladder	95%	1103.81	20 / 21	95%	11.02	477 / 504
kidney	94%	886.75	84 / 89	92%	17.78	829 / 901
intestine	97%	1321.50	938 / 966	84%	7.01	444 / 527
stomach	99%	1395.56	354 / 359	80%	7.00	228 / 286
skin	100%	1709.66	1805 / 1809	58%	5.36	272 / 472
lymph node	0%	0	0 / 0	100%	55.31	29 / 29
spleen	100%	4830.98	241 / 241	0%	0	0 / 0
ureter	0%	0	0 / 0	100%	8.43	1 / 1
blood vessel	100%	1888.69	1334 / 1335	0%	0	0 / 0
adipose	100%	2431.10	1203 / 1204	0%	0	0 / 0
peripheral blood	99%	4057.70	920 / 929	0%	0	0 / 0
ovary	22%	127.76	39 / 180	77%	5.56	331 / 430
tonsil	0%	0	0 / 0	98%	22.65	44 / 45
liver	42%	275.31	96 / 226	36%	3.08	145 / 406
heart	47%	253.82	408 / 861	0%	0	0 / 0
adrenal gland	26%	113.57	67 / 258	10%	0.56	22 / 230
brain	5%	22.89	134 / 2642	15%	1.01	106 / 705
eye	0%	0	0 / 0	8%	0.33	6 / 80
muscle	3%	11.61	23 / 803	0%	0	0 / 0
abdomen	0%	0	0 / 0	0%	0	0 / 0
bone marrow	0%	0	0 / 0	0%	0	0 / 0
diaphragm	0%	0	0 / 0	0%	0	0 / 0
gingiva	0%	0	0 / 0	0%	0	0 / 0
nasal cavity	0%	0	0 / 0	0%	0	0 / 0
nasopharynx	0%	0	0 / 0	0%	0	0 / 0
nose	0%	0	0 / 0	0%	0	0 / 0
placenta	0%	0	0 / 0	0%	0	0 / 0
spinal column	0%	0	0 / 0	0%	0	0 / 0

III. Associated gene sets

GO_0006915	Biological process	apoptotic process
GO_0043066	Biological process	negative regulation of apoptotic process
GO_0043065	Biological process	positive regulation of apoptotic process
GO_0005654	Cellular component	nucleoplasm
GO_0005737	Cellular component	cytoplasm
GO_0043027	Molecular function	cysteine-type endopeptidase inhibitor activity involved in apoptotic process
GO_0005515	Molecular function	protein binding

IV. Literature review

[source]

Gene name	TNFAIP8
Protein name	TNF alpha induced protein 8 Tumor necrosis factor alpha-induced protein 8 (TNF alpha-induced protein 8) (Head and neck tumor and metastasis-related protein) (MDC-3.13) (NF-kappa-B-inducible DED-containing protein) (NDED) (SCC-S2) (TNF-induced protein GG2-1) Tumor necrosis factor alpha-induced protein 8
Synonyms
Description	FUNCTION: Acts as a negative mediator of apoptosis and may play a role in tumor progression. Suppresses the TNF-mediated apoptosis by inhibiting caspase-8 activity but not the processing of procaspase-8, subsequently resulting in inhibition of BID cleavage and caspase-3 activation. .
Accessions	E5RIJ3 ENST00000513374.1 [O95379-4] ENST00000274456.6 [O95379-3] ENST00000503646.1 [O95379-1] O95379 D6RCM8 J3KQT8 ENST00000415806.2 ENST00000388882.5 ENST00000504771.3 [O95379-1] ENST00000504642.1

TNFAIP8 report

I. Expression across cell types

II. Expression across tissues

III. Associated gene sets

IV. Literature review